BRIDGE is a public-private consortium with the goal of developing gene-specific anticancer therapies to advance cancer treatment. The project applies new systems biology strategies to identify genes that are aberrant in cancer cells. Molecular approaches based on RNAi (RNA interference) technology then work to validate these genes as potential therapeutic targets and to test the clinical effect of inhibiting these genes or their products.

This research could lead to the development of new RNAi-based therapies as well as diagnostic markers to identify patients with the highest probability of responding to appropriately targeted therapies. It would then work to measure the success of such therapies in clinical trials. The project has a strong focus on post-doctoral training in BRIDGE consortium laboratories. The Foundation for NIH raised $1.5 million from the private sector for this project.

Partners
Anonymous Individuals
Avon Foundation